Inactivated COVID-19 Vaccine Efficacy in Those with SLE and RA

May 31, 2022

A recent study, published in Biomedicine & Pharmacotherapy, aimed to “investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs)”. Seroreactivity is the reactivity of blood serum, especially to a virus, and involves the analysis of the presence of specific antibodies. 60 SLE patients, 70 RA patients, and 35 age- and sex-matched healthy controls were recruited for the study. Serum samples, collected 2 weeks after 2 doses of the inactivated COVID-19 vaccine had been administered, were tested for immunoglobin G (IgG) and M (IgM) antibodies against SARS-CoV-2.

The results indicated that “there were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients, and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic.” More specifically, 50% of those with SLE, 57.1% of those with RA, and 65.7% of the healthy controls had IgG antibodies against SARS-CoV-2 present and 8.3% of those with SLE, 8.6% of those with RA, and 2.9% of the healthy controls had IgM antibodies against SARS-CoV-2 present.





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.